Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.41 |
| ▸ | GRK6 | P43250 | 1/20 | 0.41 |
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | CTRC | Q99895 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29799100 | 1.00 | CA12 (0.46) | CA12ACMSDGRK6HAO1P2RX3 | |
| SCHEMBL29799085 | 0.91 | HAO1 (0.44) | HAO1P2RX3DHODHPIN1FFAR1 | |
| SCHEMBL21296859 | 0.91 | HAO1 (0.44) | HAO1P2RX3DHODHPIN1FFAR1 | |
| SCHEMBL29799213 | 0.90 | CA12 (0.48) | CA12ACMSDGRK6HAO1ALPL | |
| SCHEMBL21296909 | 0.90 | CA12 (0.48) | CA12ACMSDGRK6HAO1ALPL | |
| SCHEMBL21296892 | 0.87 | KMT2A (0.43) | CA12HAO1ALPLSIRT2MIF | |
| SCHEMBL29799273 | 0.87 | KMT2A (0.43) | CA12HAO1ALPLSIRT2MIF | |
| SCHEMBL22795536 | 0.87 | MIF (0.36) | CA12ACMSDGRK6HAO1P2RX3 | |
| SCHEMBL21296953 | 0.85 | FFAR4 (0.47) | HAO1P2RX3ALPLDHODHPIN1 | |
| SCHEMBL21296979 | 0.85 | HAO1 (0.47) | CA12HAO1ALPLCTRCFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11389456-B2 | Compounds and methods for treating oxalate-related diseases | OXALURX, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2020-12-17 | — | — | US | disclosed |
| WO-2019165159-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019165159-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | XDH, PNPO, LOX | CA12 843/4885ACMSD 846/4885GRK6 1532/4885 |
| US-11389456-B2 | Compounds and methods for treating oxalate-related diseases | XDH, PNPO, LOX | CA12 843/4885ACMSD 846/4885GRK6 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.